STAT Plus Tiny PhaseBio gets the New England Journals spotlight. Can its shares rebound

STAT Plus: Tiny PhaseBio gets the New England Journal’s spotlight. Can its shares rebound?

15:00 EDT 17 Mar 2019 | STAT

PhaseBio is not loved by investors. But with its experimental drug highlighted in the New England Journal of Medicine, will its shares rebound? #ACC19

STAT Plus Tiny PhaseBio gets the New England Journals spotlight. Can its shares rebound

STAT Plus: Tiny PhaseBio gets the New England Journal’s spotlight. Can its shares rebound?

More From BioPortfolio on "STAT Plus: Tiny PhaseBio gets the New England Journal’s spotlight. Can its shares rebound?"